Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.
Colapietro A, Rossetti A, Mancini A, Martellucci S, Ocone G, Pulcini F, Biordi L, Cristiano L, Mattei V, Delle Monache S, Marampon F, Gravina GL, Festuccia C. Colapietro A, et al. Pharmaceuticals (Basel). 2021 Oct 26;14(11):1082. doi: 10.3390/ph14111082. Pharmaceuticals (Basel). 2021. PMID: 34832864 Free PMC article.
Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.
Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG. Marampon F, et al. Among authors: colapietro a. Oncotarget. 2016 Feb 2;7(5):5383-400. doi: 10.18632/oncotarget.6579. Oncotarget. 2016. PMID: 26689991 Free PMC article.
Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.
Marampon F, Gravina GL, Ju X, Vetuschi A, Sferra R, Casimiro MC, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG. Marampon F, et al. Among authors: colapietro a. Oncotarget. 2016 Sep 27;7(39):64526. doi: 10.18632/oncotarget.12267. Oncotarget. 2016. PMID: 28042139 Free PMC article. No abstract available.
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
Gravina GL, Mancini A, Marampon F, Colapietro A, Delle Monache S, Sferra R, Vitale F, Richardson PJ, Patient L, Burbidge S, Festuccia C. Gravina GL, et al. Among authors: colapietro a. J Hematol Oncol. 2017 Jan 5;10(1):5. doi: 10.1186/s13045-016-0377-8. J Hematol Oncol. 2017. PMID: 28057017 Free PMC article.
The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
Gravina GL, Mancini A, Colapietro A, Vitale F, Vetuschi A, Pompili S, Rossi G, Marampon F, Richardson PJ, Patient L, Patient L, Burbidge S, Festuccia C. Gravina GL, et al. Among authors: colapietro a. Tumour Biol. 2017 Jun;39(6):1010428317695528. doi: 10.1177/1010428317695528. Tumour Biol. 2017. PMID: 28639900 Free article.
47 results